Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Targeting Acute Leukemia with TdT-TCR-T-cell therapy

Project description

Breakthrough therapy for drug-resistant leukaemia

Acute lymphoblastic leukaemia (ALL) is a devastating blood cancer that primarily affects children and adults, often leading to relapse despite intensive treatments. Current therapies can be highly toxic and are not always effective, leaving patients with few options and a poor prognosis. There is an urgent need for safer and more targeted treatments that can eliminate cancer cells without harming healthy tissues. A novel approach using T-cell receptors (TCRs) offers new hope in this fight. In this context, the ERC-funded TTT-therapy project aims to commercialise a TCR-based immunotherapy that targets leukaemia cells while sparing healthy ones. The therapy is now progressing towards clinical trials to help ALL patients with limited treatment options.

Objective

The aim of this PoC project is to commercialize new therapy for acute lymphoblastic leukemia (ALL) developed in context of my ERC consolidator grant. T-cell receptors (TCRs) have in recent years emerged as promising therapeutic molecules in cell- and gene-therapy of cancer. I have completed the pre-clinical validation of a TCR that recognizes an HLA-bound peptide from a novel target, the nuclear enzyme terminal deoxynucleotidyl transferase (TdT-TCR). In vitro and in vivo data from four different mouse models show eradication of ALL and no indications of toxicity. T-cells genetically modified with the TdT-TCR effectively kill lymphoblastic cancer cells while sparing healthy B and T-cells, myeloid cells and hematopoietic stem cells. Funding has been secured for an investigator-initiated trial to determine safety and explore efficacy of TdT-TCR-T-cell therapy – TTT-therapy. The trial will recruit ALL patients relapsing from/refractory to standard therapy, who have a dismal prognosis and thus a great unmet medical need. To facilitate commercial development, I have created a start-up company and secured the company exclusive licenses for the patents on the TdT-TCR and the technology used for the development, on which I am the main inventor. In the proposed ERC PoC project, I and my strong team of advisers with expertise in the business development, clinical development, IPR and financial aspects needed for commercialization, will conduct a market analysis for TTT-therapy and develop an IPR and business strategy for the start-up company. Since several studies report expression of TdT in acute myeloid leukemia (AML), I will conduct laboratory research to determine if the TdT-TCR can also mediate killing of AML cells. AML patients have an overall 5-year survival of only 30% and hence a great medical need that potentially could be met by TTT-therapy. The described work has the potential to contribute to saving lives that would otherwise be lost to acute leukemia.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-POC

See all projects funded under this call

Host institution

OSLO UNIVERSITETSSYKEHUS HF
Net EU contribution
€ 20 000,00
Address
KIRKEVEIEN 166 TARNBYGGET
0450 Oslo
Norway
Region
Norge Oslo og Viken Oslo
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (2)